Trimerbody

LeadArtis is a biopharmaceutical company engaged in the development of proprietary therapeutic antibodies named Trimerbodies with higher multivalence and multispecificity than the immunoglobulins, which are currently most prevalent on the market. 
 
Our drug candidates are derived from in-house R&D and our collaborations with reference research centers and other companies. We have several proprietary programs developing in multiple therapeutic areas, including immune-oncology, which is a high-growth area for companies and investors. LeadArtis offers an opportunity to participate in the development of cutting-edge immunomodulatory therapies against cancer.
 
By creating new medicines, we can create hope for future patients suffering from cancers for which current therapies are inadequate. 
 
Trimerbody® is a registered trademark and is covered by international patents.

Latest News

Leadartis presenting at the AseBio Investor Day 2020
17-09-2020

Leadartis will be presenting its business proposal at the AseBio Investor Day (...

LEADARTIS, THE LEADING IMMUNO-ONCOLOGY COMPANY IN SPAIN, OPENS A €1 MILLION ROUND TOGETHER WITH INVEREADY, SODENA AND CDTI INNVIERTE FOR THE DEVELOPMENT OF ITS FIRST PRODUCT IN ADVANCED CANCERS
11-09-2020

LEADARTIS, a company dedicated to the development of IMMUNO-ONCOLOGICAL medicines based on its...

Investigadores crean molécula eficaz ante el progreso de células tumorales
15-11-2018

LA VANGUARDIA

Madrid, 15 nov (EFE).- Un grupo de investigadores del Hospital 12 de...